Study on the mechanism of Astragalus polysaccharide alleviating muscle atrophy in diabetic sarcopenia rats
[Objective]To explore the therapeutic effect of Astragalus polysaccharide(APS)on muscle atrophy in diabetic sarcopenia rats by acting on PI3K-AKT-FOXO1 signaling pathway and related inflammatory factors.[Methods]The diabetic animal model was constructed by one-time intraperitoneal injection of streptozotocin,and was randomly divided into model group,APS group and metformin group.After the experiment,HE staining and Western Blot were used to determine P-AKT/AKT and FOXO1 protein content in gastnemius muscle,and fluorescence quantitative qPCR was used to detect IL-6,TP53,HSF1,MMP-9 and serum biochemical index TG.[Results]Compared with model group,the muscle cells of gastrocnemius muscle in APS group were significantly improved,the cell volume was enlarged,the space was narrowed,and the inflammatory exudation was significantly reduced.In addition,the levels of P-AKT/AKT and FOXO1 protein were significantly increased in the APS group.The contents of inflammatory factor IL-6,TP53,heat shock transcription factor 1 and matrix metalloproteinase 9 decreased significantly.In terms of blood lipid,triglyceride decreased more significantly in the metformin group.[Conclusion]APS may reduce the levels of IL-6 and TP53 inflammatory factors through PI3K-AKT-FOXO1 signaling pathway,affect the activities of heat shock transcription factor 1 and matrix metalloprotein-9,and thus improve the muscle atrophy in diabetic sarcosis rats.
国家科技期刊平台
NSTL
万方数据
维普
